Arcutis Biotherapeutics Inc
(NAS:ARQT)
$
7.965
-0.665 (-7.71%)
Market Cap: 922.06 Mil
Enterprise Value: 801.92 Mil
PE Ratio: 0
PB Ratio: 4.08
GF Score: 38/100 Arcutis Biotherapeutics Inc (ARQT) Transcripts
- Q1 2024 Arcutis Biotherapeutics Inc Earnings Call TranscriptMay 14, 2024$8.13 (+1.75%)Earnings
- Q4 2023 Arcutis Biotherapeutics Inc Earnings Call TranscriptFeb 27, 2024$10.63 (+9.70%)Earnings
- Arcutis Biotherapeutics Inc ZORYVE (roflumilast) Foam Launch Call TranscriptJan 22, 2024
- Q3 2023 Arcutis Biotherapeutics Inc Earnings Call TranscriptNov 03, 2023$2.44 (+9.91%)Earnings
- Arcutis Biotherapeutics Inc Provides Positive Atopic Dermatitis Program Updates Call TranscriptSep 19, 2023
- Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Arcutis Biotherapeutics Inc Earnings Call TranscriptAug 08, 2023$9.83 (+2.61%)Earnings
- Arcutis Biotherapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Q1 2023 Arcutis Biotherapeutics Inc Earnings Call TranscriptMay 09, 2023$14.82 (+3.93%)Earnings
- Arcutis Biotherapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Q4 2022 Arcutis Biotherapeutics Inc Earnings Call TranscriptFeb 28, 2023$16.18 (+1.25%)Earnings
- Arcutis Biotherapeutics Inc Atopic Dermatitis Topline Data Call TranscriptDec 12, 2022
- Q3 2022 Arcutis Biotherapeutics Inc Earnings Call TranscriptNov 08, 2022$18.7 (+1.03%)Earnings
- Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Arcutis Biotherapeutics Inc FDA Approval Conference Call TranscriptAug 01, 2022
- Arcutis Biotherapeutics Inc Topline Data Call TranscriptJun 06, 2022
- Arcutis Biotherapeutics Inc Corporate Analyst Meeting TranscriptMar 28, 2022
- Arcutis Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Arcutis Biotherapeutics Inc DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review - Conference Call TranscriptFeb 01, 2021
- Arcutis Biotherapeutics to Discuss Positive Topline Data from Phase 2b Study of ARQ-154 - Conference Call TranscriptNov 23, 2020
- Arcutis Biotherapeutics Inc Announces Positive Topline Data from Phase 2 Seborrheic Dermatitis- Corporate Call TranscriptSep 29, 2020
- Arcutis Biotherapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Arcutis Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- 1